News > Some women report worse side effects after ovarian suppression

Some women report worse side effects after ovarian suppression

In sub-study of SOFT trial, women given tamoxifen plus ovarian suppression reported higher rates of certain menopausal symptoms than women given tamoxifen alone


The women reported their symptoms as part of the Suppression of Ovarian Function Trial (SOFT), an international study that found blocking ovarian function may lower the risk of cancer returning for some young women. The findings on symptoms were analyzed in this sub-study.



The SOFT trial was designed to evaluate tamoxifen plus ovarian suppression in premenopausal women with early-stage, hormone receptor-positive breast cancer. It also looked at how using the aromatase inhibitor exemestane (Aromasin) plus ovarian suppression compared with tamoxifen plus ovarian suppression and tamoxifen alone. Women in the trial may have had chemotherapy before joining. The study found exemestane plus ovarian suppression to be the more effective of these treatments for women who had received chemotherapy but had not gone through menopause.

The hormone estrogen makes some types of breast cancer grow. Premenopausal women normally produce estrogen in their ovaries. When these women have breast cancer that grows in response to estrogen they may be given tamoxifen, a hormonal therapy that blocks the cancer cell’s estrogen receptors. Some also may have ovarian suppression to lessen the amount of estrogen the ovaries make. In the SOFT trial, the ovaries were suppressed using either the medicine triptorelin (Trelstar), surgery to remove the ovaries, called oophorectomy, or radiation to the ovaries.

In this analysis, the SOFT researchers collected information from participating women on hormone-related side effects and the impact those had on their quality of life across different treatment types. The researchers looked at the results from women treated with tamoxifen alone, with tamoxifen plus ovarian suppression, and with exemestane plus ovarian suppression.



Participants from different treatment groups reported on quality of life measures including health, mood and any side effects experienced at the start of the study. This baseline survey was followed by new reports completed at their doctor’s office every 6 months for the next 2 years, and then once a year for another 4 years.

The analysis included 1,722 premenopausal women with early-stage, hormone receptor-positive breast cancer. They had a median age of 43 years. About half – 55 percent – had prior chemotherapy.



Compared with the tamoxifen alone group, women who received tamoxifen and ovarian suppression had worse menopausal symptoms and other symptoms early on. Women in this group:

  • Were significantly more affected by hot flashes and sweats at 6 months and 24 months. There were no differences between the groups by 60 months.
  • Showed a significantly greater loss of sexual interest at 6 months, but not at 24 months or later. They had more difficulty becoming aroused at 6 months and 24 months.
  • Had more trouble sleeping at 6 months but not later.
  • Were more likely to report vaginal dryness throughout the study. Those on tamoxifen alone had more vaginal discharge and itching at the early and middle reports.

Changes in areas such as physical well-being and mood, which are used to measure quality of life, were small and similar between the groups.

Women who had been treated with chemotherapy before the study had worse symptoms at the study’s start. Getting earlier chemotherapy did not make those women’s symptoms worse for the length of the study, results that went against what researchers had expected. Some symptoms and quality-of-life measures were even less notable during the study period in those who had chemotherapy. The researchers noted that this group also benefits most from ovarian suppression.

Results for women given exemestane plus ovarian suppression were not formally compared to the other two groups, but showed more problems with sexual function, vaginal dryness, and bone and joint pain.


What this means for you

When your primary treatment for breast cancer ends, you may feel relieved. You might also be worried about what comes next. If you are still premenopausal and have hormone receptor-positive disease, your doctor might suggest ovarian suppression plus hormonal therapy. This can lower the amount of estrogen in your body. Yet the possibility of side effects may concern you.

Tamoxifen, exemestane, and ovarian suppression each can cause menopausal symptoms on their own. The addition of ovarian suppression to tamoxifen or exemestane increases these.

In this analysis, women reported their experiences while on hormonal therapy and ovarian suppression. Like symptoms of natural menopause, the symptoms caused by treatment lessened over time.

Talk with your healthcare team about the treatments you are considering or are receiving to weigh the benefits against possible difficulties. Ask your oncology nurse or other provider about ways to manage specific symptoms. Volunteers on our Breast Cancer Helpline also can suggest approaches that may help.

Ribi, K, Luo, W, Berhhard, J, et al. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. Journal of Clinical Oncology. Published ahead of print in March 2016. DOI: 10.1200/JCO.2015.64.8675.


This article was supported by the Grant or Cooperative Agreement Number 1 U58 DP005403, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.


Related resources

Early menopause

08/26/22 | BY: Ann Honebrink

If you are premenopausal or perimenopausal, breast cancer treatments — including surgery to remove ovaries, chemotherapy, and hormonal therapy — may cause your menstrual periods to stop for a while or, in some cases, permanently.

Read More | 9 Min. Read |

Menopausal symptoms

08/12/22 | BY: Anne Katz

Some treatments can cause temporary menopause, and others can cause permanent menopause. Even if you went through menopause naturally before treatment, treatment can sometimes bring new symptoms, or changes in how you've experienced symptoms.

Read More | 10 Min. Read |

Sexual side effects

08/12/22 | BY: Anne Katz

It’s normal to lose interest in sex at times after diagnosis and during treatment. Breast cancer treatments or the cancer itself can cause fatigue, discomfort, pain, and other side effects that impact your sexual desire and activity.

Read More | 16 Min. Read

Side Effects

02/04/22 | BY: Sameer Gupta

Side effects are unwanted reactions to medical treatments. For many people, side effects are among the most upsetting parts of being treated for breast cancer. Still, there are many things you can do to help prevent and manage side effects.

Read More | 8 Min. Read

Talking with your partner about sex

08/13/20 | BY: Don S. Dizon, Michael Krychman, Anne Katz, Helen Coons, Sabitha Pillai-Friedman, Susan Kellogg-Spadt

Breast cancer can have physical and emotional impacts on your sexual life. Communication is key to keeping relationships strong, but it’s not always easy to start a conversation about sex. Here our community offers some tips to get the dialogue started.

Read More | 6 Min. Read

Ovarian suppression


Ovarian suppression is surgery, radiation therapy or medicine that is used in premenopausal women to stop the ovaries from working.

Read More | 4 Min. Read

If you feel pain during sex

11/04/19 | BY: Don S. Dizon

Breast cancer treatment can cause side effects that affect your sexual life, including pain during intercourse or penetration. If this is happening, it’s very important to talk with your healthcare provider.

Read More | 5 Min. Read

Types of hormonal therapy

11/04/19 | BY: Jennifer Winn

Hormonal therapy medicines are put into classes based on how they interact with the body’s natural hormones estrogen and progesterone. Some stop the body from making estrogen, while others prevent estrogen from helping the cancer cell grow.

Read More | 6 Min. Read


11/04/19 | BY: Jennifer Winn

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

Read More | 6 Min. Read

Gonadotropin releasing hormone (GnRH) agonists

10/07/19 | BY: H. Irene Su

The gonadotropin releasing hormone agonists, or GnRH agonists, are a class of injectable medicines offered to pre- and perimenopausal women with breast cancer in order to temporarily suppress, or slow, ovarian function.

Read More | 5 Min. Read